SunRISe-1 bladder cancer trial posts Phase 2b results; TiTan myeloma trial registered

Two items surfaced in registry activity this period, one with new results and one newly registered study.

• Janssen Research & Development's Phase 2b trial "SunRISe-1" (NCT04640623) testing TAR-200 with or without cetrelimab, or cetrelimab alone, in high-risk non-muscle invasive bladder cancer unresponsive to BCG posted results on 2026-07-29. The study enrolled 220 participants.¹ For Cohorts 1, 2, and 3, the primary outcome was overall complete response rate, defined as the percentage of participants meeting criteria including negative cystoscopy and cytology, measured through a clinical cutoff of July 3, 2025.¹ Cohort 4's primary outcome was disease-free survival, tracking time to recurrence of high-risk disease, progression to muscle invasive disease, or death.¹
• The Polish Myeloma Consortium's Phase 3 trial "TiTan" (NCT07740486), with Johnson & Johnson as a collaborator, remains not yet recruiting. The study is designed to evaluate whether maintenance therapy with teclistamab in combination with talquetamab can improve treatment outcomes compared with standard maintenance therapy with daratumumab and lenalidomide in participants with newly diagnosed multiple myeloma who remain MRD-positive after ASCT.² The study will enroll approximately 248 adult participants.² The primary goal is to determine how many patients achieve undetectable MRD after 12 months of treatment together with a complete response to therapy.²